Estuary Biotherapeutics, Inc. — SEC Form D Filing
Estuary Biotherapeutics, Inc. filed an SEC Form D on October 16, 2026, reporting $40.65M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 16, 2026
- Amount reported
- $40.65M
- Round stage
- Series A, aligned with the company's launch backed by a $93 million Series A commitment to advance early candidates into the clinic.
- Industry
- Biotechnology
- Website
- https://www.estuarybio.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Autosomal dominant polycystic kidney disease causes progressive renal failure without curative genetic treatments available to address its underlying mutations.
Solution
Estuary Biotherapeutics develops kidney-directed adeno-associated virus gene therapies designed to deliver functional genetic components to restore polycystin proteins.
Why now
Recent advancements in kidney-targeted viral capsid engineering enable precise gene delivery directly to renal cells that was previously unachievable.
Source: SEC EDGAR Form D filing